Clinical Trial Update: A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy [Phase 3]

View source ↗

Summary

Phase 3 extension study of Engensis (VMDN-003-2) in painful diabetic peripheral neuropathy has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy

Drugs mentioned

• Engensis (VM202)

Snippet

Sponsor: Helixmith Co., Ltd. | Conditions: Diabetic Peripheral Neuropathy | Phase 3 | Status: COMPLETED | Results posted: 2025-01-16